Finally a cure?

Alzheimer; News from the web:

By the close of this year, the Indianapolis-based Fortune 500 pharmaceutical company Lilly , whose products have included the antidepressant Prozac and human insulin, will release the results of Expedition 3, a study testing a drug that targets amyloid in persons with mild stage dementia caused by Alzheimer’s disease. Its subjects are unique. They don’t simply have Alzheimer’s disease diagnosed by a careful history and exam. They have a brain scan showing amyloid accumulation.

Read all about it HERE

Power outage causes Alzheimer’s?

Alzheimer; News from the web:

In new research appearing in the journal Alzheimer’s and Dementia, Diego Mastroeni, Paul Coleman and their colleagues at the ASU-Banner Neurodegenerative Disease Research Center (NDRC) and the Biodesign Center for Bioenergetics investigate the role of mitochondria in Alzheimer’s disease pathology. Mitochondria act as energy centers for cells and are of central importance in health and disease.

The study builds on earlier work suggesting gene mutations affecting may be critical in the development— and pitiless progression— of the disease.

Read all about it HERE